CA3106618A1 - Compositions of surface-modified therapeutically active particles by ultra-rapid freezing - Google Patents

Compositions of surface-modified therapeutically active particles by ultra-rapid freezing Download PDF

Info

Publication number
CA3106618A1
CA3106618A1 CA3106618A CA3106618A CA3106618A1 CA 3106618 A1 CA3106618 A1 CA 3106618A1 CA 3106618 A CA3106618 A CA 3106618A CA 3106618 A CA3106618 A CA 3106618A CA 3106618 A1 CA3106618 A1 CA 3106618A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
agents
tff
excipient
inhaler
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3106618A
Other languages
English (en)
French (fr)
Inventor
Iii Robert O. Williams
Chaeho MOON
Alan B. Watts
John J. Koleng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA3106618A1 publication Critical patent/CA3106618A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3106618A 2018-07-24 2019-07-24 Compositions of surface-modified therapeutically active particles by ultra-rapid freezing Pending CA3106618A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862702674P 2018-07-24 2018-07-24
US62/702,674 2018-07-24
PCT/US2019/043202 WO2020023614A1 (en) 2018-07-24 2019-07-24 Compositions of surface-modified therapeutically active particles by ultra-rapid freezing

Publications (1)

Publication Number Publication Date
CA3106618A1 true CA3106618A1 (en) 2020-01-30

Family

ID=69181152

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3106618A Pending CA3106618A1 (en) 2018-07-24 2019-07-24 Compositions of surface-modified therapeutically active particles by ultra-rapid freezing

Country Status (12)

Country Link
US (1) US20210338671A1 (https=)
EP (1) EP3827260A4 (https=)
JP (2) JP7611813B2 (https=)
KR (1) KR20210038583A (https=)
CN (1) CN112673257B (https=)
AU (1) AU2019311086A1 (https=)
BR (1) BR112021001290A2 (https=)
CA (1) CA3106618A1 (https=)
EA (1) EA202190331A1 (https=)
IL (1) IL280342A (https=)
MX (1) MX2021000796A (https=)
WO (1) WO2020023614A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186754A2 (en) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
US11918646B2 (en) 2017-12-11 2024-03-05 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
CN113398079B (zh) * 2020-03-16 2024-01-19 鲁南制药集团股份有限公司 一种注射用氟达拉滨冻干粉
BR112023001929A2 (pt) 2020-09-03 2023-03-14 Philip Morris Products Sa Composições em pó ativas de baixa higroscopicidade
US20230301919A1 (en) * 2020-09-03 2023-09-28 Philip Morris Products S.A. Freeze dried low hygroscopicity active powder compositions
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
CN117241786A (zh) * 2021-03-12 2023-12-15 德克萨斯大学系统董事会 使用基于悬浮液的薄膜冷冻制备干燥粉末的方法
US12015755B2 (en) 2021-03-25 2024-06-18 Korea Advanced Institute Of Science And Technology Real-time omnidirectional stereo matching method using multi-view fisheye lenses and system thereof
CN113484469B (zh) * 2021-06-30 2022-11-18 中国科学院青海盐湖研究所 水合盐体系相变储能材料纳米尺度相分离的原位表征方法
CN116440084A (zh) * 2022-01-07 2023-07-18 浙江萃泽医药科技有限公司 一种可吸入的药物粉末制剂及其制备方法
AU2023366929A1 (en) 2022-10-25 2025-05-08 Veradermics, Incorporated Compositions and methods of use for modified release minoxidil

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08310969A (ja) * 1995-05-22 1996-11-26 Lion Corp 固形薬品組成物及びその製造方法
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
CN1750811A (zh) * 2001-10-19 2006-03-22 巴克斯特国际公司 在冷冻水基质中包括颗粒的稳定组合物
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
US9061027B2 (en) * 2004-08-27 2015-06-23 Board Of Regents, The University Of Texas System Enhanced delivery of drug compositions to treat life threatening infections
WO2007011396A2 (en) * 2004-10-29 2007-01-25 President And Fellows Of Harvard College Particles for treatment of pulmonary infection
US8361439B1 (en) * 2005-01-04 2013-01-29 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
WO2007053923A2 (en) * 2005-11-11 2007-05-18 Biolab Sanus Farmacêutica Ltda. Solid pharmaceutical composition comprising agglomerate nanoparticles and a process for producing the same
WO2011046842A1 (en) * 2009-10-12 2011-04-21 The Regents Of The University Of California Targeted nanoclusters and methods of their use
US10973763B2 (en) * 2011-06-17 2021-04-13 Berg Llc Inhalable pharmaceutical compositions
US9801855B2 (en) * 2012-03-07 2017-10-31 National Institute Of Pharmaceutical Education And Research (Niper) Nanocrystalline solid dispersion compositions and process of preparation thereof
JP6940416B2 (ja) * 2015-05-01 2021-09-29 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 多剤脆性マトリックス組成物

Also Published As

Publication number Publication date
EA202190331A1 (ru) 2021-06-17
JP2021530551A (ja) 2021-11-11
BR112021001290A2 (pt) 2021-04-27
CN112673257A (zh) 2021-04-16
JP2024170583A (ja) 2024-12-10
MX2021000796A (es) 2021-06-15
US20210338671A1 (en) 2021-11-04
AU2019311086A1 (en) 2021-02-04
CN112673257B (zh) 2025-02-25
KR20210038583A (ko) 2021-04-07
WO2020023614A1 (en) 2020-01-30
IL280342A (en) 2021-03-25
EP3827260A1 (en) 2021-06-02
JP7611813B2 (ja) 2025-01-10
EP3827260A4 (en) 2022-05-04

Similar Documents

Publication Publication Date Title
US20210338671A1 (en) Compositions of surface-modified therapeutically active particles by ultra-rapid freezing
Duret et al. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties
JP6082049B2 (ja) 閉塞性または炎症性気道疾患を治療するための２種以上の活性成分を含有する粒子の乾燥粉末製剤
ES2814336T3 (es) Partículas de agregado
JP6940416B2 (ja) 多剤脆性マトリックス組成物
CA2898700C (en) Deamorphization of spray-dried formulations via spray-blending
CN105101955A (zh) 至少包含两种通过喷雾干燥以增加制剂稳定性而得到的干粉的组合物
Sahakijpijarn et al. Pharmaceutical cryogenic technologies
RU2697867C2 (ru) Частицы для ингаляции, содержащие комбинацию антихолинергического, кортикостероидного и бета-адренергического средств
Liu et al. Formulation of a novel fixed dose combination of salmeterol xinafoate and mometasone furoate for inhaled drug delivery
US20220313611A1 (en) Methods to prepare dry powders using suspension based thin film freezing
Surasarang et al. Pharmaceutical cryogenic technologies
HK40050243A (en) Compositions of surface-modified therapeutically active particles by ultra-rapid freezing
US20230263816A1 (en) Pharmaceutical compositions for delivery of remdesivir by inhalation
WO2024026412A1 (en) Thin film freezing methods and compositions formulated from dispersed active agents
Moon et al. Thin-Film Freeze-Drying Process for Versatile Particles for Inhalation Drug Delivery
Moon et al. and Robert O. Williams III1
WO2024151838A1 (en) Co-crystals with thin-film freeze-drying process to enhance delivery
Traini et al. Preparation and evaluation of single and co-engineered combination inhalation carrier formulations for the treatment of asthma
Moon Development of high potency voriconazole nanoaggregates for dry powder inhalation

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240724

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240724

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250424

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250425

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250425

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250425

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250520

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250722

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250722

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250808

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251203

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260106

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260106